August 25, 2016 1:39 AM ET

Pharmaceuticals

Company Overview of Sucampo Pharmaceuticals, Inc.

Executive Profile

Peter S. Greenleaf

Chairman and Chief Executive Officer, Sucampo Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 9 different industries.

See Board Relationships
46$3,152,375
As of Fiscal Year 2015

Background

Mr. Peter S. Greenleaf has been the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since January 1, 2016 and March 03, 2014 respectively. Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. He served as President of MedImmune, LLC (also known as MedImmune, Inc.). He also served as President of MedImmune Ventures, a wholly owned venture capital fund within ...

Corporate Headquarters

805 King Farm Boulevard
Rockville, Maryland 20850

United States

Phone: 301-961-3400
Fax: 301-961-3440

Board Members Memberships

Director
2014-Present
Chairman and Chief Executive Officer
2015-Present
Director, Member of Compensation Committee and Member of Audit Committee
2016-Present
Director

Education

MBA
Saint Joseph's University
BS
Western Connecticut State University

Other Affiliations

Annual Compensation

Salary$565,288
Total Annual Compensation$565,288

Stocks Options

All Other Compensation$8,843
Exercisable Options$350,000
Exercisable Options Value$3,428,000
Unexercisable Options$860,000
Unexercisable Options Value$6,756,700
Total Value of Options$10,184,700
Total Number of Options$1,210,000

Total Compensation

Total Annual Cash Compensation$1,166,510
Total Short Term Compensation$565,288
Other Long Term Compensation$8,843
Total Calculated Compensation$3,152,375
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science Committee
Progenics Pharmaceuticals, Inc.
$597.1K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
$691.5K
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals, Inc.
$720.0K
John Anthony Sedor Chairman, Chief Executive Officer and Member of Nominating Committee
Pernix Therapeutics Holdings, Inc.
--
Allan Oberman Chief Executive Officer and Director
Sagent Pharmaceuticals, Inc.
$244.7K
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sucampo Pharmaceuticals, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.